|
1
|
Imagawa A, Hanafusa T, Miyagawa J and
Matsuzawa Y: A novel subtype of type 1 diabetes mellitus
characterized by a rapid onset and an absence of diabetes-related
antibodies. Osaka IDDM Study Group. N Engl J Med. 342:301–307.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
American Diabetes Association, . Diagnosis
and classification of diabetes mellitus. Diabetes Care. 37 (Suppl
1):S81–S90. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hanafusa T and Imagawa A: Fulminant type 1
diabetes: A novel clinical entity requiring special attention by
all medical practitioners. Nat Clin Pract Endocrinol Metab.
3:36–45. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Imagawa A, Hanafusa T, Uchigata Y,
Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I,
Maruyama T and Makino H: Different contribution of class II HLA in
fulminant and typical autoimmune type 1 diabetes mellitus.
Diabetologia. 48:294–300. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kawasaki E, Imagawa A, Makino H, Uga M,
Abiru N, Hanafusa T, Uchigata Y and Eguchi K: Differences in the
contribution of the CTLA4 gene to susceptibility to fulminant and
type 1A diabetes in Japanese patients. Diabetes Care. 31:1608–1610.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fabris P, Betterle C, Floreani A, Greggio
NA, de Lazzari F, Naccarato R and Chiaramonte M: Development of
type 1 diabetes mellitus during interferon alfa therapy for chronic
HCV hepatitis. Lancet. 340:5481992. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Uto H, Matsuoka H, Murata M, Okamoto T,
Miyata Y, Hori T, Ido A, Hirono S, Hayashi K and Tsubouchi H: A
case of chronic hepatitis C developing insulin-dependent diabetes
mellitus associated with various autoantibodies during interferon
therapy. Diabetes Res Clin Pract. 49:101–106. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Diana J, Simoni Y, Furio L, Beaudoin L,
Agerberth B, Barrat F and Lehuen A: Crosstalk between neutrophils,
B-1a cells and plasmacytoid dendritic cells initiates autoimmune
diabetes. Nat Med. 19:65–73. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Munakata W, Ohashi K, Yamauchi N and
Tobinai K: Fulminant type I diabetes mellitus associated with
nivolumab in a patient with relapsed classical Hodgkin lymphoma.
Int J Hematol. 105:383–386. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Okamoto M, Okamoto M, Gotoh K, Masaki T,
Ozeki Y, Ando H, Anai M, Sato A, Yoshida Y, Ueda S, et al:
Fulminant type 1 diabetes mellitus with anti-programmed cell
death-1 therapy. J Diabetes Investig. 7:915–918. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hughes J, Vudattu N, Sznol M, Gettinger S,
Kluger H, Lupsa B and Herold KC: Precipitation of autoimmune
diabetes with anti-PD-1 immunotherapy. Diabetes Care. 38:e55–e57.
2015.PubMed/NCBI
|
|
12
|
Hofmann L, Forschner A, Loquai C,
Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal
JS, Göppner D, et al: Cutaneous, gastrointestinal, hepatic,
endocrine, and renal side-effects of anti-PD-1 therapy. Eur J
Cancer. 60:190–209. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gaudy C, Clévy C, Monestier S, Dubois N,
Préau Y, Mallet S, Richard MA, Grob JJ, Valéro R and Béliard S:
Anti-PD1 pembrolizumab can induce exceptional fulminant type 1
diabetes. Diabetes Care. 38:e182–e183. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yonekura K, Basaki Y, Chikahisa L, Okabe
S, Hashimoto A, Miyadera K, Wierzba K and Yamada Y: UFT and its
metabolites inhibit the angiogenesis induced by murine renal cell
carcinoma, as determined by a dorsal air sac assay in mice. Clin
Cancer Res. 5:2185–2191. 1999.PubMed/NCBI
|
|
15
|
Longley DB, Harkin DP and Johnston PG:
5-fluorouracil: Mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hoff PM and Pazdur R: UFT plus oral
leucovorin: A new oral treatment for colorectal cancer. Oncologist.
3:155–164. 1998.PubMed/NCBI
|
|
17
|
NIH consensus conference, . Adjuvant
therapy for patients with colon and rectal cancer. JAMA.
264:1444–1450. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Benson AB III, Schrag D, Somerfield MR,
Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J,
McAllister P, Van Cutsem E, et al: American society of clinical
oncology recommendations on adjuvant chemotherapy for stage II
colon cancer. J Clin Oncol. 22:3408–3419. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schmoll HJ, Van Cutsem E, Stein A,
Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde
CJ, Balmana J, Regula J, et al: ESMO consensus guidelines for
management of patients with colon and rectal cancer. A personalized
approach to clinical decision making. Ann Oncol. 23:2479–2516.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Adachi J, Mimura M, Gotyo N and Watanabe
T: The development of fulminant type 1 diabetes during chemotherapy
for rectal cancer. Intern Med. 54:819–822. 2015. View Article : Google Scholar : PubMed/NCBI
|
